Which CGRP monoclonal antibody is listed for cluster headache prevention?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which CGRP monoclonal antibody is listed for cluster headache prevention?

Targeting CGRP signaling with monoclonal antibodies offers a focused preventive approach for cluster headaches. Among these therapies, galcanezumab is the CGRP monoclonal antibody that has been listed (and studied/approved) for preventing episodic cluster headaches. It works by binding CGRP and reducing its ability to activate the trigeminovascular system involved in cluster attacks, providing a targeted preventive option beyond traditional prophylactics. The other options are not CGRP-targeting antibodies: verapamil is a calcium channel blocker used for cluster headache prevention but not a CGRP monoclonal antibody; lithium is a mood stabilizer with some use in headache management but not a CGRP-targeted therapy; corticosteroids can be used short-term for cluster headache management but are not monoclonal antibodies targeting CGRP.

Targeting CGRP signaling with monoclonal antibodies offers a focused preventive approach for cluster headaches. Among these therapies, galcanezumab is the CGRP monoclonal antibody that has been listed (and studied/approved) for preventing episodic cluster headaches. It works by binding CGRP and reducing its ability to activate the trigeminovascular system involved in cluster attacks, providing a targeted preventive option beyond traditional prophylactics.

The other options are not CGRP-targeting antibodies: verapamil is a calcium channel blocker used for cluster headache prevention but not a CGRP monoclonal antibody; lithium is a mood stabilizer with some use in headache management but not a CGRP-targeted therapy; corticosteroids can be used short-term for cluster headache management but are not monoclonal antibodies targeting CGRP.

More practice questions